maralixibat · Livmarli
Small molecule
Evidence outlook
Approved: Alagille Syndrome
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (4)
- Cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
- Pruritus associated with cholestasis in Alagille syndrome (and PFIC)
- Cholestatic pruritus in Alagille syndrome patients aged 1 year and older (CAN108, CANbridge)
- Cholestatic pruritus in patients with Alagille syndrome 2 months of age and older (marketing authorisation under exceptional circumstances); PFIC added
Company guidance: regulatory filing expected first half of 2027 (Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We plan to submit a supplemental New Drug Application (“sNDA”) for Livmarli based on the EXPAND study in the first half of 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ICONIC NCT02160782 · Alagille Syndrome The trial included a randomized, triple-blinded placebo-controlled withdrawal period, but the primary endpoint was a surrogate biomarker rather than a clinical outcome, and only 29 participants entered that comparison. The primary comparison favored maralixibat and was statistically significant, but the study cannot be considered strong evidence because of the surrogate endpoint and the limited sample size. Registry: NCT02160782 | 2 | Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18 2020-05-28 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Ileal bile acid transporter (IBAT) drugs
volixibat. Compare all 2 Ileal bile acid transporter (IBAT) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Maralixibat (Livmarli): this drug | Approved | Small molecule | Ileal bile acid transporter (IBAT) | Partial signal | NCT04185363: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score (From Baseline to Weeks 75-78): The Primary Cohort -1.633 score on a scale (Standard Deviation 1.4416) | PFIC Cohort -1.602 score on a scale (Standard Deviation 1.3649) NCT03905330: Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort (MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.): Primary Cohort Maralixibat -1.718 Score on a scale (95% CI -2.272 to -1.163) | Primary Cohort Placebo -0.628 Score on a scale (95% CI -1.136 to -0.121) | |
| Volixibat | Phase 2(overall) | Small molecule | Ileal bile acid transporter (IBAT) | not yet graded | No reviewed efficacy summary |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Livmarli (maralixibat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
2028 (1)
March 2028 (1)
What to watch
2029 (1)
January 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent